Inventor · disambiguated record
Patrick Engelberts
Also filed as: ENGELBERTS PATRICK
7 granted patents·13 pending applications·27 citations·filing 2008–2025
81Inventor score
Files withGENMAB AS20
Top patents by PatentIndex Score
20 records- 0193US10544220B2Bispecific antibodies against CD3 and CD20GENMAB AS·Filed 2016·Granted Jan 28, 2020·18 cites·12 claims
- 0292US11359015B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2016·Granted Jun 14, 2022·6 cites·24 claims
- 0391US11008399B2AntibodiesGENMAB AS·Filed 2020·Granted May 18, 2021·2 cites·22 claims
- 0488US11130819B2AntibodiesGENMAB AS·Filed 2021·Granted Sep 28, 2021·1 cites·30 claims
- 0585US2024392032A1AntibodiesGENMAB AS·Filed 2024·Application pending·0 cites
- 0677US2023027394A1Humanized or chimeric cd3 antibodiesGENMAB AS·Filed 2022·Application pending·0 cites
- 0777US2022389101A1Humanized or chimeric cd3 antibodiesGENMAB AS·Filed 2022·Application pending·0 cites
- 0877US2022380464A1Humanized or chimeric cd3 antibodiesGENMAB AS·Filed 2022·Application pending·0 cites
- 0976US11970544B2AntibodiesGENMAB AS·Filed 2021·Granted Apr 30, 2024·0 cites·31 claims
- 1073US11261254B1AntibodiesGENMAB AS·Filed 2021·Granted Mar 1, 2022·0 cites·30 claims
- 1171US11814437B2Antibodies binding to CD30 and CD3GENMAB AS·Filed 2022·Granted Nov 14, 2023·0 cites·16 claims
- 1271US2022324980A1AntibodiesGENMAB AS·Filed 2022·Application pending·0 cites
- 1371US2025340647A1AntibodiesGENMAB AS·Filed 2025·Application pending·0 cites
- 1469US2024228641A9Antibodies binding to cd30 and cd3GENMAB AS·Filed 2023·Application pending·0 cites
- 1568US2020277397A1AntibodiesGENMAB AS·Filed 2020·Application pending·0 cites
- 1667US2021292418A1AntibodiesGENMAB AS·Filed 2021·Application pending·0 cites
- 1759US2020199231A1Bispecific antibodies against cd3 and cd20GENMAB AS·Filed 2019·Application pending·0 cites
- 1856US2023365714A1Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3GENMAB AS·Filed 2021·Application pending·0 cites
- 1950US2023257479A1Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancerGENMAB AS·Filed 2020·Application pending·0 cites
- 2041US2011091473A1Novel antibody therapiesGENMAB AS·Filed 2008·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Patrick Engelberts files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →